CN114555625B - 用于将剂递送至细胞和组织中的新型肽、组合物和方法 - Google Patents

用于将剂递送至细胞和组织中的新型肽、组合物和方法 Download PDF

Info

Publication number
CN114555625B
CN114555625B CN202080055898.6A CN202080055898A CN114555625B CN 114555625 B CN114555625 B CN 114555625B CN 202080055898 A CN202080055898 A CN 202080055898A CN 114555625 B CN114555625 B CN 114555625B
Authority
CN
China
Prior art keywords
cell
nuc1
tissue
decorin
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080055898.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN114555625A (zh
Inventor
R·库马尔-辛格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts University
Original Assignee
Tufts University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts University filed Critical Tufts University
Publication of CN114555625A publication Critical patent/CN114555625A/zh
Application granted granted Critical
Publication of CN114555625B publication Critical patent/CN114555625B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080055898.6A 2019-07-02 2020-07-02 用于将剂递送至细胞和组织中的新型肽、组合物和方法 Active CN114555625B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962869831P 2019-07-02 2019-07-02
US62/869,831 2019-07-02
PCT/US2020/040720 WO2021034418A2 (en) 2019-07-02 2020-07-02 Novel peptide, compositions and method for delivery of agents into cells and tissues

Publications (2)

Publication Number Publication Date
CN114555625A CN114555625A (zh) 2022-05-27
CN114555625B true CN114555625B (zh) 2025-02-25

Family

ID=74659924

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080055898.6A Active CN114555625B (zh) 2019-07-02 2020-07-02 用于将剂递送至细胞和组织中的新型肽、组合物和方法

Country Status (9)

Country Link
US (2) US11713337B2 (https=)
EP (1) EP3994151A4 (https=)
JP (1) JP7581264B2 (https=)
KR (1) KR20220039725A (https=)
CN (1) CN114555625B (https=)
AU (1) AU2020332268B2 (https=)
CA (1) CA3144963A1 (https=)
IL (1) IL289516A (https=)
WO (1) WO2021034418A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3100276A1 (en) 2018-06-06 2019-12-12 Massachusetts Institute Of Technology Circular rna for translation in eukaryotic cells
WO2026005189A1 (ko) * 2024-06-27 2026-01-02 이엔셀 주식회사 안구 세포 또는 조직을 표적하는 펩타이드 및 이를 포함하는 바이러스 캡시드 단백질 및 바이러스 벡터

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101848722A (zh) * 2007-04-17 2010-09-29 J·胡威特 具有改进的溶解性的新型肽两亲物及其使用方法
CN107636017A (zh) * 2015-04-10 2018-01-26 费尔丹生物公司 用于改进多肽负荷向靶真核细胞的细胞质转导的效率的基于多肽的穿梭剂，其用途、及与其相关的方法和试剂盒

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5211657A (en) * 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
DE19827457C1 (de) * 1998-06-19 2000-03-02 Medigene Ag Strukturprotein von AAV, seine Herstellung und Verwendung
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
JP3635462B2 (ja) * 2000-05-31 2005-04-06 国立医薬品食品衛生研究所長 アデノウイルスベクター
SE0301431D0 (sv) * 2003-05-19 2003-05-19 Dermagen Novel antimicrobial peptides
AU2008295509A1 (en) * 2007-08-29 2009-03-12 Tufts University Methods of making and using a cell penetrating peptide for enhanced delivery of nucleic acids, proteins, drugs, and adenovirus to tissues and cells, and compositions and kits
EP2187907A2 (en) * 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Use of tyr-w-mif-1 and urocortin 2 as therapeutic agents
CN102869384B (zh) * 2009-06-22 2016-01-13 伯纳姆医学研究所 使用带有c-端元件的肽和蛋白质的方法和组合物
US20130158103A1 (en) * 2011-11-23 2013-06-20 The Curators Of The University Of Missouri Method of Tissue-Selective Targeted Gene Transfer
EP3076792B1 (en) * 2013-12-04 2020-11-11 Newleaf Symbiotics, Inc. Compositions and methods for improving lettuce production
US10316061B2 (en) * 2014-10-02 2019-06-11 Temple University Of The Commonwealth System Of Higher Education Synthesis of cell penetrating peptides for drug delivery and stem cell applications
CN108064229B (zh) * 2015-03-12 2021-12-28 三洋化成工业株式会社 蛋白质组合物的制造方法和蛋白质组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101848722A (zh) * 2007-04-17 2010-09-29 J·胡威特 具有改进的溶解性的新型肽两亲物及其使用方法
CN107636017A (zh) * 2015-04-10 2018-01-26 费尔丹生物公司 用于改进多肽负荷向靶真核细胞的细胞质转导的效率的基于多肽的穿梭剂，其用途、及与其相关的方法和试剂盒

Also Published As

Publication number Publication date
US20230340024A1 (en) 2023-10-26
AU2020332268A1 (en) 2022-02-24
KR20220039725A (ko) 2022-03-29
CN114555625A (zh) 2022-05-27
WO2021034418A2 (en) 2021-02-25
JP7581264B2 (ja) 2024-11-12
JP2022538903A (ja) 2022-09-06
WO2021034418A3 (en) 2021-04-01
AU2020332268B2 (en) 2025-04-24
US11713337B2 (en) 2023-08-01
EP3994151A2 (en) 2022-05-11
IL289516A (en) 2022-03-01
EP3994151A4 (en) 2023-07-19
US20220204562A1 (en) 2022-06-30
CA3144963A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
BR112021007221A2 (pt) proteínas inteínas e seus usos
US20200040360A1 (en) Genetic construct
JP5643237B2 (ja) 光受容細胞のアポトーシスを抑制する方法
US20250221936A1 (en) Engineered hemichannels, engineered vesicles, and uses thereof
CA2901439C (en) Peptides for use in the topical treatment of retinal neurodegenerative diseases, in particular in early stages of diabetic retinopathy and other retinal diseases in which neurodegeneration plays an essential role
US20120315256A1 (en) Use of transforming growth factor - beta 1 (tgf-b1) inhibitor peptides for the treatment of corneal fibrosis and/or haze
JP6640311B2 (ja) 軟骨細胞の細胞外基質由来ペプチド
US20230340024A1 (en) Novel peptide, compositions and method for delivery of agents into cells and tissues
JP2018531624A (ja) 設計されたメガヌクレアーゼを使用した網膜色素変性症の治療
Liu et al. siRNA silencing of gene expression in trabecular meshwork: RhoA siRNA reduces IOP in mice
KR101214364B1 (ko) 수퍼옥사이드 디스뮤테이즈 융합 단백질을 함유하는 안과 질환 예방 또는 치료용 약제학적 조성물
Kumar et al. Cell-Penetrating chaperone Nuc1 for Small-and Large-Molecule delivery into retinal cells and tissues
US20160144055A1 (en) Gene therapy vector for treatment of steroid glaucoma
WO2025083169A1 (en) Combination of a vegf inhibitor and a complement pathway inhibitor for treating ocular disorders
EA048046B1 (ru) Новый пептид, композиции и способ доставки агентов в клетки и ткани
US20230135501A1 (en) Gene therapy
US20230190869A1 (en) Peptide inhibitors of guanine nucleotide exchange factor h-1
US20250177573A1 (en) Materials & Methods for Treatment of Macular Degeneration
CN113727990B (zh) 短合成肽及其治疗视网膜退化性疾病和/或组织损伤的用途
Read Non-Viral Gene Therapy for the Treatment of Retinal Degeneration

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant